Benzinga | Jul 14, 2021 06:28AM EDT

scPharma's Furoscix Can Potentially Cut Hospital Admission/Readmission Costs For Heart Failure Patients

* scPharmaceuticals Inc (NASDAQ:SCPH) announced top-line results from its FREEDOM-HF study evaluating overall and heart failure-related costs of treating congestion in patients with chronic heart failure.

* Patients were treated with the Company's investigational Furoscix, post-discharge from the emergency department, compared to a historical comparator group treated with intravenous furosemide in the inpatient hospital setting.

* Due to a statistically significant reduction observed in 30-day heart failure-related costs in patients who received Furoscix in the interim analysis, enrollment was stopped early.

* The mean difference in heart failure-related costs between the two groups was $17,753 per study subject, favoring the Furoscix group.

* Subjects who received Furoscix did not require an initial heart failure hospitalization, and all but one remained out of the hospital for heart failure for the subsequent 30-day period.

* In the comparator group, 100% of the patients were initially hospitalized, and 10.6% had a heart failure-related readmission.

* The most common adverse events with Furoscix were infusion site pain, bruising, and dizziness, with no serious adverse events observed.

* scPharmaceuticals' management will host a conference call and live webcast today at 8:30 am ET.

* Price Action: SCPH shares are up 4.56% at $6.88 premarket on the last check Wednesday.